Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Serina Therapeutics ( (SER) ) has issued an announcement.
On September 9, 2025, Serina Therapeutics announced securing up to $20 million in financing to advance the registrational trial of SER-252 for Parkinson’s disease. This funding, led by Board Director Greg Bailey, MD, will support the Phase 1b clinical study under the 505(b)(2) NDA pathway. The financing structure allows flexibility in capital deployment and includes potential additional proceeds through warrant issuance. The trial aims to evaluate the safety, tolerability, and pharmacokinetics of SER-252, a novel apomorphine therapy designed for continuous dopaminergic stimulation in advanced Parkinson’s patients. The study will be conducted in the U.S. and Australia, with key milestones anticipated in 2025 and 2026.
The most recent analyst rating on (SER) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.
Spark’s Take on SER Stock
According to Spark, TipRanks’ AI Analyst, SER is a Neutral.
Serina Therapeutics faces significant financial and technical challenges, with severe inefficiencies and a bearish market trend. The negative P/E ratio and lack of dividend yield further highlight valuation concerns. While the advancement of SER-270 is a positive step, it does not sufficiently mitigate the overall risks.
To see Spark’s full report on SER stock, click here.
More about Serina Therapeutics
Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug product candidates for neurological diseases and other indications. The company utilizes its proprietary POZ Platform™ technology to enhance the efficacy and safety of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-based drug conjugates. Serina is headquartered in Huntsville, Alabama.
Average Trading Volume: 123,737
Technical Sentiment Signal: Sell
Current Market Cap: $52.18M
See more data about SER stock on TipRanks’ Stock Analysis page.